A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Breast Neoplasms
  • Immunotoxins
  • Maytansine
  • Molecular Targeted Therapy
  • Quinazolines
  • Receptor, ErbB-2

abstract

  • T-DM1 is well tolerated and has single-agent activity in patients with HER2-positive MBC who have previously received both approved HER2-directed therapies and multiple chemotherapy agents. T-DM1 may be an effective new treatment for this patient population.

publication date

  • September 10, 2012

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2011.40.5902

PubMed ID

  • 22649126

Additional Document Info

start page

  • 3234

end page

  • 41

volume

  • 30

number

  • 26